bms-986369
Small moleculeexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2022 (NCT05350800)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06535399 | Phase 1 | Aug 15, 2024 | Bristol-Myers Squibb, Celgene |
| NCT06035497 | Phase 1/Phase 2 (Phase 2) | Nov 20, 2023 | Bristol-Myers Squibb |
| NCT05788081 | Phase 2 | Aug 31, 2023 | Austin Health, Barwon Health, Bristol-Myers Squibb, Eastern Health, Canada, Murdoch University, Olivia Newton-John Cancer Research Institute |
| NCT05567510 | Phase 1 | Oct 20, 2022 | Bristol-Myers Squibb |
| NCT05350800 | Phase 1 | Sep 12, 2022 | Bristol-Myers Squibb |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 5 | 3 | 2 | 2022 |
| Austin Health | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Barwon Health | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Celgene | For profit | 1 | 1 | 1 | 2024 |
| Eastern Health, Canada | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Murdoch University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Olivia Newton-John Cancer Research Institute | Academic/Hospital | 1 | 1 | 1 | 2023 |
7 organizations
Page 1 / 1